Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 46, Issue 4, 2005, Pages 497-507

  Dermime, Said ^a   Aljurf, Mahmoud D ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Idiotype; Immunotherapy; Non Hodgkin's lymphoma; T lymphocytes; Tumor vaccine

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; VIRUS VACCINE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE MODEL; DRUG CONJUGATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE REACTION; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRAL GENE THERAPY;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MODELS, IMMUNOLOGICAL;

EID: 17844396955     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/104281904000025104     Document Type: Review

References (71)

1. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-535.
2. Owaidah TM, Aljurf MD. The evolving role of monoclonal antibodies and dendritic cell therapy in hematologic malignancies. Hematology 2002;7:265-272.
3. Dermime S, Armstrong AC, Hawkins RE, Stern PL. Cancer vaccines and immunotherapy. Br Med Bull 2002;62:149-162.
4. Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992;58:143-175.
5. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccinated with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulate potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
6. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognised by T cells. Immunol Today 1997;18:267-268.
7. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10:281-287.
8. Grey HM, Ruppert J, Vitiello A, Sidney J, Kast WM, Kubo RT, Sette A. Class I MHC-peptide interactions: structural requirement and functional implications. Cancer Serv 1995;22:37-49.
9. Pieters J. MHC class II restricted antigen processing and presentation. Adv Immunol 2000;75:159-208.
10. June C, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15: 321-331.
11. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10-16.
12. Podack ER. Functional significance of two cytolytic pathways of cytotoxic lymphocytes. J Leukocyte Biol 1995;57:548-552.
13. Inaba K, Steinman RM, Pack MW, Aya H, Inaba M, Sudo T, Wolpe S, Schuler G. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 1992;175: 1157-1167.
14. Nair SK, Boczkowski D, Snyder D, Gilboa E. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 1997;27: 589-597.
15. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36:39-44.
16. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engelman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
17. Tjoa B, Erickson S, Barren R 3rd, Ragde H, Kenny G, Boynton A, Murphy G. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995;27:63-69.
18. Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003;101:977-982.
19. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:65-72.
20. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
21. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-336.
22. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997;186:1213-1221.
23. Armstrong AC, Dermime S, Allison C, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL, Hawkins RE. Immunisation with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor protective immunity and identification of an idiotype-specific T cell epitope. J Immunol 2002;168:3983-3991.
24. Timmerman JM, Casper CB, Lambert SL, Syrengelas AD, Levy R. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 2001;97:1370-1377.
25. Armstrong AC, Dermime S, Mulryan K, Stern PL, Bhattacharyya T, Hawkins RE. Adoptive transfer of anti-idiotypic T cell cure mice from disseminated B cell lymphoma. J Immunother 2004;27:227-231.
26. Luna-Fineman S, Lee JE, Wesley PK, Clayberger C, Krensky AM. Human cytotoxic T-lymphocytes specific for autologous follicular lymphoma recognize immunoglobulin in a major histocompatibility complex restricted fashion. Cancer 1992;70:2181-2186.
27. H complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur J Immunol 1997;27:1043-1047.
28. Osterroth F, Garbe A, Fisch P, Veelken H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 2000;95:1342-1349.
29. Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Meth 1986;89:61-72.
30. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-1526.
31. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 1997;89:3129-3135.
32. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 1996;93:10972-10977.
33. Miller G, Pillarisetty VG, Shah AB, Lahrs S, Xing Z, DeMatteo RP. Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. J Immunol 2002;169:2875-2885.
34. George AJT, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol 1987;138:628-634.
35. George AJT, Folkard SG, Hamblin TJ, Stevenson FK. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 1988;141:2168-2174.
36. King CA, Wills MR, Hamblin TJ, Stevenson FK. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell Immunol 1993;147:411-424.
37. Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol 1987;138:1289-1296.
38. Campbell MJ, Esserman L, Levy R. Immunotherapy for established murine B cell lymphoma, combination of idiotype immunisation and cyclophosphamide. J Immunol 1988;141:3227-3233.
39. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990;145:1029-1036.
40. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. J Immunol 1994;153:4775-4787.
41. Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 2000;164:4797-4803.
42. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self-tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999;17:253-258.
43. Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, Oppenheim JJ, Kwak LW. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001;167:6644-6653.
44. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-1215.
45. Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 1996;88:580-589.
46. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-1177.
47. Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, Stevenson FK. Idiotypic vaccination against human B cell lymphoma, rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 1994;83:3279-3288.
48. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000;18:927-974.
49. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B cell lymphoma. Nature 1993;362:755-758.
50. Benvenuti F, Burrone OR, Efremov DG. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection. Gene Ther 2000;7:605-611.
51. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Natl Med 1998;4:1281-1286.
52. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Natl Med 1996;2:1038-1041.
53. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 1999;162:4790-4795.
54. Hakim I, Levy S, Levy R. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996;157:5503-5511.
55. Hawkins RE, Russell SJ, Marcus R, Ashworth LJ, Brissnik J, Zhang J, Winter G, Bleehen NM, Shaw MM, Williamson L et al. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027. Hum Gene Ther 1997;8: 1287-1299.
56. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002;62:5845-5852.
57. Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M, Moingeon P. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett 2000;74:11-25.
58. Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Scholm J. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999;17:332-337.
59. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-3973.
60. Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 1996;26:2671-2679.
61. Schultze JL. Why do B cell lymphoma fail to elicit clinically sufficient immune responses. Leuk Lymphoma 1999; 32:223-236.
62. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156:3858-3865.
63. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999;162:5003-5010.
64. Goodwin RG, Din WS, Davis-Smith T, Anderson DM, Gimpel SD, Sato TA, Maliszewski CR, Brannan CI, Copeland NG, Jenkins NA. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993;23:2631-2641.
65. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17.
66. Meziane el K, Bhattacharyya T, Armstrong AC, Qian C, Hawkins RE, Stern PL, Dermime S. The use of adenoviruses encoding CD40L and/or IL-2 against B cell lymphoma. Int J Cancer 2004;111:910-920.
67. Briones J, Timmerman J, Levy R. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res 2002;62:3195-3199.
68. Borrello IM, Sotomayor EM. Cancer vaccines for hematologic malignancies. Cancer Control 2002;9:138-151.
69. Armstrong A, Dermime S. Developing effective cancer vaccines: design and monitoring are critical. Br J Cancer 2001;84:1433-1436.
70. McCarthy H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Br J Haematol 2003;123:770-781.
71. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99:3319-3325.